No plague case has been confirmed, and no government orders have been announced, but outbreak-linked stocks jumped anyway.

  • NVAX surged 20%, EBS gained 14%, ARCT rose 13% and MRNA climbed 7% amid the Russian plague scare.
  • The rally broadened to protective-equipment, antiviral and immune-profiling stocks, with LAKE gaining 15% and APT and NNVC each rising 13%.
  • Russian authorities called the regional situation stable, while the WHO assessed the public risk as low.

A Russian lab worker’s unexplained death in a plague research institute sparked a rally across vaccine and biodefense stocks on Monday, with Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS) and Arcturus Therapeutics (ARCT) advancing as retail investors speculated about federal contracts and further gains.

NVAX surged 20%, EBS climbed 14%, ARCT gained 13% and MRNA rose 7%. Buying spread to protective-equipment suppliers, testing companies and antiviral developers as traders revived familiar outbreak bets.

The rally also extended to protective-equipment makers Alpha Pro Tech (APT), which rose 13% on Monday, and Lakeland Industries (LAKE), which gained 15%. Antiviral developer NanoViricides (NNVC) climbed 13%, immune-profiling company Virax Biolabs (VRAX) advanced 10%, and smallpox-drug maker Siga Technologies (SIGA) added 3%. 

Cancer-immunotherapy developer ImmunityBio (IBRX), which also featured in retail discussions about government demand, edged up 1%.  

Trump’s Russia Offer Fuels Spending Hopes

“We’ll help,” Trump said on Monday, calling the situation a “big problem for Russia,” Reuters reported. The remarks came after the death of Darya Shipilova, a 28-year-old lab technician at the Irkutsk Anti-Plague Research Institute in Siberia. She developed pneumonia of unknown origin, prompting quarantine measures and medical observation of people who had contact with her.

Russia’s public health agency, Rospotrebnadzor, said samples contained no microorganisms associated with her professional duties and called the regional epidemiological situation stable. 

The WHO said that the risk to the general population appeared low based on available unofficial information. U.S. Secretary of State Marco Rubio also urged measured attention, calling the situation a “cause for focus,” according to CNN.

The uncertainty nevertheless gave traders a familiar catalyst: the prospect that heightened preparedness could lead to government purchases.

Vaccine Makers Ride Outbreak Bets

Novavax, Moderna and Arcturus have commercial vaccines, but their products do not target plague. Novavax developed Nuvaxovid, a protein-based COVID-19 vaccine containing its Matrix-M adjuvant. Matrix-M enhances immune responses and can be incorporated into other vaccines, giving the company broader vaccine-development and licensing exposure.

Moderna markets COVID-19 vaccines, including Spikevax, and the RSV vaccine mRESVIA. Its mRNA tech makes it a familiar name in emerging-pathogen trades. 

Meanwhile, Arcturus has the commercial COVID-19 vaccine Kostaive and is developing ARCT-2304, an experimental H5N1 pandemic-influenza vaccine. BARDA fully funds the candidate’s Phase 1 study.

Stockpile Suppliers And PPE Makers Rally

Emergent has a direct connection to government purchasing through its medical-countermeasure portfolio. BioThrax and Cyfendus are anthrax vaccines, while ACAM2000 is a smallpox and mpox vaccine. Tembexa, another portfolio product, is a smallpox antiviral. Its $24 million BARDA contract modification for Cyfendus, announced last month, shows its procurement model. 

Siga supplies TPOXX, a smallpox antiviral, to the Strategic National Stockpile. Lakeland and Alpha Pro Tech provide protective equipment. Lakeland supplies protective clothing, while Alpha Pro Tech manufactures disposable garments, masks and face shields. 

Antiviral And Immunotherapy Names Join Rally

Virax Biolabs focuses on immune-response detection and T-cell profiling, including applications in post-acute infection syndromes such as Long COVID. NanoViricides is developing NV-387, an antiviral drug candidate. Because plague is bacterial, its rally reflects broader outbreak sentiment rather than an established plague-treatment opportunity.

Meanwhile, ImmunityBio markets Anktiva, a cancer immunotherapy, and develops immune-cell platforms.

How Do Retail Traders Feel About Outbreak Bets?

On Stocktwits, retail sentiment for NVAX and EBS was ‘extremely bullish’ amid ‘extremely high’ message volume. ARCT drew ‘bullish’ sentiment with ‘normal’ chatter, while MRNA sentiment remained ‘neutral’ despite ‘high’ message volume. 

One user on EBS said: “Contract awards are in bound....good timing with the Russia plague news fueling the momentum!!” The user added: “See you at 15++.. Might even hit 20 by year-end!” Another user on NVAX sees a return to “operation warp speed” and “throwing billions at NVAX.”

One user on APT drew parallels with a previous outbreak trade: “Hantavirus took APT from $4.50 to $7.50 this May. The plague should take us even higher.” Another user on NNVC noted that “every time there is a pandemic fear this makes a massive run.”

So far this year, NVAX has gained 87%, MRNA has surged 589% and ARCT has climbed 139%, while EBS remains down 41%. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.<